Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. SFA_Sales_Revenues_August_2024_espi.pdfSales revenues for August 2024

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 102 / 2024
Date of issue: 2024-09-20
Short name of the issuer
SOPHARMA AD
Subject
Sales revenues for August 2024
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
Sofia, Bulgaria, September 20, 2024 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for August 2024 the Company recorded a decrease in sales of 3% compared to the same month of the previous year, incl. 30% increase in domestic sales and 16% decrease in export sales.
For the period from the beginning of 2024, the Company recorded a decrease in sales of 7%, incl. 8% increase of domestic sales and 15% decrease in export sales.
Annexes
File Description
SFA_Sales_Revenues_August_2024_espi.pdf
SFA_Sales_Revenues_August_2024_espi.pdf		 Sales revenues for August 2024

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2024-09-20 Ognian Donev Executive Director
20240920_130324_0063193207_SFA_Sales_Revenues_August_2024_espi.pdf

Pobierz